Published in
American Association for the Advancement of Science, Science Translational Medicine, 607(13), 2021
DOI: 10.1126/scitranslmed.abd3904
Links
Tools
The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia
Journal article published in 2021 by
Zachary F. Caffall 
,
Bradley J. Wilkes ,
Ricardo Hernández-Martinez ,
Joseph E. Rittiner ,
Jennifer T. Fox,
Kanny K. Wan ,
Miranda K. Shipman ,
Steven A. Titus,
Ya-Qin Zhang,
Samarjit Patnaik ,
Matthew D. Hall ,
Matthew B. Boxer,
Min Shen,
Zhuyin Li,
David E. Vaillancourt
and other authors.
,
Bradley J. Wilkes ,
Ricardo Hernández-Martinez ,
Joseph E. Rittiner ,
Jennifer T. Fox,
Kanny K. Wan ,
Miranda K. Shipman ,
Steven A. Titus,
Ya-Qin Zhang,
Samarjit Patnaik ,
Matthew D. Hall ,
Matthew B. Boxer,
Min Shen,
Zhuyin Li,
David E. Vaillancourt
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Ritonavir, identified by a DYT1 dystonia in vitro drug screen, corrects neuronal firing response and white matter deficits in the DYT1 mouse brain.